Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$9.93
-$0.14(-3.63%)
At close: 4:00 PM EST
$9.93
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$2.19 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)1.18M
Market Cap
$521.01M
Enterprise Value$352.04M
Total Cash (Recent Filing)$236.45M
Total Debt (Recent Filing)$8.94M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 18, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding60,795,210
10 Day Avg. Volume980,796
30 Day Avg. Volume1,176,539
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-406.52
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$30.00Price Target Upside202.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Registrational Clinical EfficacyRobust, durable registrational signals (deep responses to 52 weeks and immunotherapy-free patients) materially de-risk regulatory approval and underpin a potential first-in-class position in neuroimmunology. Durable single-dose efficacy supports long-term market differentiation and lower chronic treatment costs.
Commercial Leadership Build-outInstalling a veteran CCO with proven neurology/rare-disease launch experience strengthens commercialization readiness. This supports durable capabilities in access, pricing, and launch execution, reducing execution risk as the company transitions from clinical to commercial-stage operations.
Low Leverage / Positive EquityA relatively clean balance sheet with minimal debt and positive equity provides structural financial flexibility to fund late-stage trials and initial commercialization steps without immediate heavy interest burdens. Low leverage reduces refinancing risk compared with highly indebted peers.
Bears Say
Zero Revenue ProfileSustained zero revenue means the business remains entirely pre-commercial and dependent on trial outcomes and external financing. This structural absence of commercial cash flow limits reinvestment ability and makes strategic plans contingent on successful launches and fundraising events.
High Cash BurnPersistent, large negative operating and free cash flow reflects accelerating spend to support registrational programs and scale-up. This creates a durable financing requirement, increasing dilution risk and constraining strategic optionality until commercial revenues or favorable financing materialize.
Negative ROE And Declining EquityDeeply negative ROE and falling equity signal erosion of shareholder value from operating losses. Over the medium term, this trend pressures the balance sheet and heightens reliance on external capital, which can force dilutive financings or unfavorable terms that affect long-term investor returns.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $2.19 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $521.01M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 89 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.752 by $0.092.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.68.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 60,795,210 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.752. Following the earnings report the stock price went up 5.376%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.00 (202.11% Upside)
$30.00 (202.11% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
258.57%
12-Months-Change
Fundamentals
Return on Equity
-81.87%
Trailing 12-Months
Asset Growth
-1.39%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$30.00
▲(202.11% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
23.23% Insiders
5.66% Mutual Funds
33.70% Other Institutional Investors
32.89% Public Companies and Individual Investors